Drugs Targeting the PD-1/PD-L1 Pathway. A small, first-in-human trial of the anti-PD-1 drug nivolumab reported promising results, and
Therefore, the study of the combined application of anti TIM-3 and anti PD-1/PD-L1 drugs may ameliorate the resistance of PD-1/PD-L1, save T cell failure, and improve the prognosis of patients
by J Li 2024 Cited by 2The study aimed to provide a complete toxicity profile and toxicity spectrum for anti-PD-1 and anti-PD-L1 drugs.
In twenty-three trials, the anti-PD-1/PD-L1 inhibitor alone group was compared with the control group, and in thirteen trials, the anti-PD-1/PD-L1 inhibitors plus other drugs group was compared
melanoma that is resistant to immunotherapy drugs known as PD-1 inhibitors Patients with advanced melanoma can get an anti-PD-1 treatment
A hypothetical explanation for the improved efficacy of anti‐PD1 drugs compared with anti‐PD‐L1 antibodies could be that anti PD‐1 antibodies are able to inhibit the binding of PD‐1 not only to PD‐L1 but also to PD‐L2, which is an important interaction that also inhibits the activation of T cells. 28 In fact, previous data
by PT Nghiem 2024 Cited by 1322anti–PD-1 or anti–PD-L1 drugs. The current study was undertaken to assess the efficacy of pembrolizumab, an anti–PD-1 therapy, in
Therefore, the study of the combined application of anti TIM-3 and anti PD-1/PD-L1 drugs may ameliorate the resistance of PD-1/PD-L1, save T cell failure, and improve the prognosis of patients
by J Li 2024 Cited by 2The study aimed to provide a complete toxicity profile and toxicity spectrum for anti-PD-1 and anti-PD-L1 drugs.
Comments